Device Trial Radar · NCT03635424
Medtronic Transcatheter Aortic Valve Replacement (TAVR) Low Risk Bicuspid Study
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
150
Actual
Start
Oct 30, 2018
Primary completion
Nov 13, 2019
Study completion Dec 2030
Sponsor
- Lead sponsor
- Medtronic CardiovascularPublic (MDT)
- Sponsor type
- Industry
- First posted
- Aug 17, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the trial is to evaluate the procedural safety and efficacy of the Medtronic TAVR system in patients with bicuspid aortic anatomy and severe aortic stenosis at low risk for SAVR
Conditions
- Bicuspid Aortic Valve
Interventions
Medtronic TAVR SystemsDevice
Treatment of patients with bicuspid aortic anatomy and severe aortic stenosis at low risk for SAVR with Medtronic Evolut PRO and Evolut R systems
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety: Percent of Participants With All-Cause Mortality or Disabling Stroke Rate at 30 Days Post-procedure.Time frame: 30 days
- Efficacy: Percent of Participants Who Meet All Device Success Criteria at 30 Days Post-procedure.Time frame: 7 days
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
Abrazo Arizona Heart Hospital
Phoenix, Arizona
Scripps Memorial Hospital La Jolla
La Jolla, California
Los Robles Hospital & Medical Center
Thousand Oaks, California
22 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.